About Index Trending news
Analyze
Top 50 Pricing
CareDx

CareDx

CareDx

AlloMap is a way to non-invasively test cardiac transplant patients for their risk of acute cellular rejection, graft failure, and death.

Elsewhere

Alexa global traffic share

Twitter followers

Latest funding Show all
Post-IPO equity
$22,170,000
Debt financing
$15,000,000
Employees

Team size

50+
Locations
HQ
Headquarters

No recent coverage

Index constantly checks hot and trending companies for their latest activity. We haven't gotten to this company yet, but if you follow it you'll be the the first to know when CareDx makes some noise.